3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Gynecologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
47
Lung Neoplasms
23
Carcinoma, Hepatocellular
23
Small Cell Lung Carcinoma
16
Cholangiocarcinoma
10
Breast Neoplasms
10
Urinary Bladder Neoplasms
9
Biliary Tract Neoplasms
9
Neoplasms
8
Neoplasm Metastasis
8
Liver Neoplasms
8
Pancreatic Neoplasms
6
Carcinoma
6
Endometrial Neoplasms
5
Triple Negative Breast Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Gallbladder Neoplasms
4
Carcinoma, Transitional Cell
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Bile Duct Neoplasms
3
Adenocarcinoma
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Respiratory Tract Neoplasms
2
Pathologic Complete Response
2
Oropharyngeal Neoplasms
2
Neoplasms by Histologic Type
2
Interventions
Oxaliplatin
24
Fluorouracil
20
Capecitabine
16
pembrolizumab
15
Nivolumab
15
Leucovorin
13
Trastuzumab
9
fludarabine
8
Paclitaxel
8
Drug Therapy
8
Docetaxel
8
Cyclophosphamide
8
S 1 (combination)
7
trastuzumab deruxtecan
6
Specimen Handling
6
Cisplatin
6
Magnetic Resonance Spectroscopy
5
Bevacizumab
5
zolbetuximab
4
Irinotecan
4
Biopsy
4
zimberelimab
3
sintilimab
3
fludarabine phosphate
3
atezolizumab
3
aldesleukin
3
XELOX
3
Surgical Procedures, Operative
3
Ramucirumab
3
Radiotherapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
durvalumab
×
90 days
×
Clear all
NCT04379596
2026-05-13
DG-03
AstraZeneca
Phase 2
Recruiting
450 enrolled
NCT02734004
2026-04-20
MEDIOLA
AstraZeneca
Phase 1/2
Active not recruiting
264 enrolled
32 charts